The GW4 Alliance (Bath, Bristol, Cardiff and Exeter universities GW4) formally launched their new One Health antimicrobial resistance research consortium this week [Wednesday 16 June]. The World Health Organisation cites antimicrobial resistance (AMR) as one of the most significant risks facing the world. AMR threatens global health and development as it impacts on human, animal and plant health and also our environment, water safety and food security.
The GW4 AMR Alliancehas been established to tackle this global challenge and become the UKs leading interdisciplinary One Health AMR research consortium, recognised worldwide.
A launch event showcasing GW4s cross-disciplinary AMR research collaborations and some of the One Health AMR projects and programmes being undertaken by GW4 teams and their collaborators took place on Wednesday [16 June] and included talks from University of Bristol researchers who discussed some of their latest findings from AMR research projects.
Antimicrobial resistance where bacterial, fungal, viral and parasitic infections become resistant to existing antimicrobial drugs is an increasing global societal threat, as there is no matching increase in new antibiotics or new therapies to help treat patients infections.
The COVID-19 pandemic has brought the pandemic of AMR into sharper focus. Antimicrobial use, which drives the emergence of AMR, increased in many intensive care units around the world, as clinicians mitigated the development of secondary bacterial and fungal infections in acutely ill hospitalised patients. AMR is a slower moving, silent pandemic but requires urgent action now to stop resistance expanding and find drugs to treat these infections.
The GW4 AMR Alliance builds on and enhances the GW4 universities strong and diverse portfolio of AMR research. Its vision is to tackle AMR using a One Health approach and to be the partner of choice for future AMR research consortia funding to help mitigate the urgent threat of AMR.
During the launch, Dr Kristen Reyher, leader of BristolsAMR Forceresearch group at Bristol Vet School, Matthew Avison, Professor of Molecular Bacteriology from Bristols School of Cellular and Molecular Medicine, and Helen Lambert, Professor of Medical Anthropology at Bristol Medical School, addressed AMR known unknowns as well as the link between climate change and AMR, and presented their latest research findings from projects in Thailand, Argentina and China.
Professor Avison, lead PI of the One Health Drivers of AMR in Thailand (OH-DART)project, discussed the key levers that could be pulled to help mitigate the threat of AMR in the country which, in 2010 was estimated to have caused 38,000 deaths and an economic loss of 1.2 billion US$ per year. This is mostly due to antibacterial resistance (ABR) which is common in bacteria isolated from humans, animals and the environment. He also discussed a recent paper modelling the impacts of antimicrobial usage changes in farming and human medicine.
Dr Reyher presented the latest findings from the Bristol-led One Health Selection and Transmission of Antimicrobial Resistance (OH-STAR) study and their implications for surveillance of AMR on farms, including advice about sampling from the same sites on farms, controlling for temperature in sampling and using a consistent sampling technique.
Professor Lambert, lead PI of the UK-China AMR Partnership Hub STAR-CHINA, discussed the social and cultural drivers which underpin the threat of AMR such as antibiotic prescribing and environmental exposure via water use practices, highlighting the need for interventions that alter AMR transmission pathways to take patterns of human behaviour into account.
Dr Timothy Jinks, Head of the Drug-Resistant Infections Programme at theWellcome Trust, who is delivering the keynote lecture, said: Containing and controlling AMR requires collaborative, long-term, interdisciplinary and sustainable research taking a global One Health approach. It is great news that the GW4 AMR Alliance is launching to increase understanding, development and implementation of effective interventions.
GW4s proven academic excellence in AMR research across disciplines and across institutions is demonstrated by a portfolio of AMR relevant research funding in excess of 40m.
Dr Joanna Jenkinson, GW4 Alliance Director, commented: Our strategic initiative is in total accord with the G7 Health Ministers recent communique (on 4 June) which outlined the need to act on the growing pandemic of AMR with clear leadership, bold science-based actions and a One Health approach, recognising and understanding that the health of humans, animals, plants and their shared environment are inextricably interlinked. The GW4 has fostered collaborative AMR projects at scale to achieve more than our institutions can individually. We are also proud to support our early career researchers (ECR) through our Crucible programme on Interdisciplinary Approaches to AMR and opportunities to apply for seed funding. We are delighted that one new ECR AMR community, further supported by our GW4 Generator Award funding scheme, is contributing a presentation at the launch today on their project to find new antibiotic leads.
AMR disproportionately affects low-and-middle income countries and the research being showcased today demonstrates our global reach with collaborative GW4 projects taking place in Thailand, China, Bangladesh, Argentina, India and here in the UK. GW4 researchers are exploring what drives the emergence of AMR in different settings e.g. the environment (particularly in aquatic systems from industrial and domestic waste), livestock farming, aquaculture and healthcare.
Identifying the drivers of AMR will help to help modify them by informing policy and implementing interventions to mitigate this rising threat. In the UK alone, there was a nine per cent increase in deaths caused by drug-resistant infections between 2017 and 2018.
Chair of the GW4 AMR Alliance, Prof Eshwar Mahenthiralingam (Cardiff University), said: This is a very exciting and timely consortium bringing the considerable AMR research strengths across the GW4 universities together to work as one cohesive unit to drive forward our understanding of, and to develop new interventions for containing and controlling AMR.
About the GW4 AMR Alliance
The GW4 Alliance Bath, Bristol, Cardiff and Exeter universities (GW4) are developing initiatives at scale that recognise the combined research strengths of the Alliance. The new GW4 AMR Alliance joins a number of global challenge research programmes (including climate) designed to foster new regional, national and global research partnerships to tackle major global challenges at scale.
The AMR Alliance is taking a One Health approach to tackle the growing threat of AMR. A 12-strong Steering Group draws together key members from the GW4s AMR research community to drive the programme forward, using cross-institutional, synergistic, interdisciplinary research that maximises engagement, translation and impact. The University of Bristol is represented by Professor Matthew Avison (School of Cellular and Molecular Medicine and Bristol AMR lead), Professor Helen Lambert (Bristol Medical School and UKRI Challenge Leader for Global Health) and Dr Kristen Reyher (Bristol Veterinary School).
About Bristol AMR
TheBristol AMRinterdisciplinary research network is led by a cross-faculty management committee comprising AMR research investigators from all six faculties.
Since 2015, the Bristol AMR research community has received 17.2 million of AMR research funding including grants awarded from the UKRI 'Tackling AMR A Cross-Council AMR initiative'. Funded projects include EPSRC BristolBridge, ESRC AMR Research Champion (Prof Helen Lambert) and three large consortium awards for AMR Themes 2 (BBSRC-led), 3 (NERC-led) and 4 (ESRC-led).
Bristol AMR investigators work across all disciplines to help tackle AMR, including the discovery of new antibiotics, the development of novel antimicrobial materials to prevent infection, rapid diagnostics for AMR, understanding behaviours to promote the responsible use of antimicrobials in healthcare and veterinary medicine, using data linkage to improve the use of antibiotics in healthcare and understanding how different regulatory systems in human and animal healthcare drive global AMR.
Bristol AMR investigators take a global One Health approach and work with collaborators across the UK and in low-and-middle income countries. Projects include an MRC/DoHSC 'AMR in a Global Context' award to study the drivers of AMR in Thailand; two MRC/Newton Fund UK-China Partnership Programmes to identify the key determinants of antimicrobial use and strategies to reduce the burden of AMR in China; a DoHSC GAMRIF/CONICET UK-Argentina awardlooking at future-proofing antibacterial resistance risk management surveillance and stewardship in the Argentinian farming environment; an MRC South Africa-UK Drug Discovery Partnership Hub to find new antibiotics from biodiverse-rich habitats and an EPSRC GCRF funded project to help develop nanoparticle based rapid diagnostics for tuberculosis with collaborators in Kenya.
Bristol also leads the 4 million Medical Research Foundation National PhD Training Programme in AMR Research to train next generation of AMR researchers through its multidisciplinary AMR studentships its national training cohort of 150 PhD students studying AMR across the UK.
More:
June: gw4amr-launch | News and features - University of Bristol
- Exercise promotes a molecular profile in muscle: Research - January 21st, 2023
- Molecular Diagnostics Laboratory < Laboratory Medicine - January 4th, 2023
- Molecular cloning - Wikipedia - December 18th, 2022
- Trends in Molecular Medicine | Journal - ScienceDirect - December 10th, 2022
- Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases... - December 2nd, 2022
- Nuclear Medicine and Molecular Imaging Week: October 2-8, 2022 - October 29th, 2022
- Biochemistry & Molecular Biology | Medicine - October 29th, 2022
- Cellular and Molecular Medicine | Faculty of Medicine - October 21st, 2022
- Molecular Diagnostics > Fact Sheets > Yale Medicine - October 21st, 2022
- Expert Reviews in Molecular Medicine | Cambridge Core - October 13th, 2022
- UT Southwestern ranked top health care institution globally for published research by Nature Index - UT Southwestern - October 13th, 2022
- Common Antibiotics Are Losing Their Potency. Researchers Pinpoint Mechanism to Restore It. - NYU Langone Health - October 13th, 2022
- expert reaction to study looking at integrating human stem cell-derived brain-like tissue in the brains of newborn rats - Science Media Centre - October 13th, 2022
- HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery - Yahoo Finance - October 13th, 2022
- UVA Discovers Key Driver of High Blood Pressure - UVA Health Newsroom - October 13th, 2022
- Postdoctoral Fellow in Lung Cancer Genomics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311727 - Times Higher Education - October 13th, 2022
- Common cold may increase the risk of long Covid - Earth.com - October 13th, 2022
- Caris' Precision Oncology Alliance Welcomes The Cancer Institute at The University of Tennessee Medical Center - PR Newswire - October 13th, 2022
- Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics - Yahoo... - October 13th, 2022
- Molecular Test Could Improve Early Detection of Pancreatic Cancer - Technology Networks - October 13th, 2022
- UTSW researchers identify key player in cellular response to stress - EurekAlert - October 4th, 2022
- New Antibody Demonstrates Therapeutic Benefits Against Alzheimers - SciTechDaily - October 4th, 2022
- Mount Sinai study uncovers mechanisms of reactive oxygen species in stem cell function and inflammation prevention - EurekAlert - October 4th, 2022
- NovoPath Pushes the Limits of Laboratory Information Systems with Integrated Workflows for Genetic and Molecular Testing - PR Newswire - October 4th, 2022
- Postdoctoral Fellow in Bioinformatics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311073 - Times Higher Education - October 4th, 2022
- Breast Cancer Awareness | Nick Jacobs | An unlikely partnership: The United States Army Space and Missile Defense Command and the Joyce Murtha Breast... - October 4th, 2022
- Tackling resistance to HIF2 drugs with an RNA-based therapy - UT Southwestern - October 4th, 2022
- OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis - Business... - October 4th, 2022
- SIMATS organizes Induction Ceremony - Afternoonnews - Afternoon News - October 4th, 2022
- ExPath Grad Student Madeline Mayday Awarded Grant from the NIDDK Cooperative Centers of Excellence in Hematology - Yale School of Medicine - September 25th, 2022
- Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes - Business Wire - September 25th, 2022
- New Startups Built From UC Davis Innovations Drive Solutions in Food, Health and Agriculture - University of California, Davis - September 25th, 2022
- Scientists Discover New Cancer Treatment - The Morning News - September 25th, 2022
- Rewriting the Textbook for Precision Medicine - Technology Networks - September 25th, 2022
- Biden says 'The pandemic is over,' but health experts disagree - Chief Healthcare Executive - September 25th, 2022
- Discovery Illuminates How Parkinson's Disease Spreads in The Brain - Weill Cornell Medicine Newsroom - September 25th, 2022
- AI Used to Determine Cause of Alzheimer's and Related Disorders - Inside Precision Medicine - September 25th, 2022
- Looking Ahead in the Treatment of Breast Cancer - Targeted Oncology - September 25th, 2022
- Researchers identify potential biomarker to distinguish two aggressive types of brain tumors in children - EurekAlert - September 25th, 2022
- New study reveals breakthrough infections increase immunity to COVID-19 - OHSU News - September 25th, 2022
- Coronavirus Today: Who's dying of COVID-19 now? - Los Angeles Times - September 25th, 2022
- Hoag Named Radiopharmaceutical Therapy Center of Excellence, Publishes Results of Breast and Prostate Cancer Trials - PR Newswire - September 8th, 2022
- Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines - Yahoo Finance - September 8th, 2022
- Scientists urged the Biden administration to launch an Operation Warp Speed to develop inhaled COVID vaccines. China beat the U.S. to the punch -... - September 8th, 2022
- Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic... - September 8th, 2022
- Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader Phase... - September 8th, 2022
- Biden administration says the once-a-year shot phase of the COVID-19 pandemic has arrived - The Boston Globe - September 8th, 2022
- ICCBS welcomes students of MPhil and PhD Programs 2022 - The Academia Mag - September 8th, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 308114 - Times... - September 8th, 2022
- Congratulations to our NRF award winners | UCT News - University of Cape Town News - September 8th, 2022
- Patients with some forms of aggressive esophageal cancers may benefit from treatment targeting how cells self-regulate - EurekAlert - September 8th, 2022
- Molecular Medicine (M.Sc.) - Georg-August-Universitt Gttingen - August 30th, 2022
- Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated... - August 30th, 2022
- Feinstein Institutes Get $3M From Lupus Research Alliance to Study Remission and Future Therapies - Business Wire - August 30th, 2022
- Unlocking the Power of Precision Medicine the Rheumatology Example - Technology Networks - August 30th, 2022
- When to trust your covid test results and when to question them | Mint - Mint - August 30th, 2022
- Molecular Diagnostics Market Report 2022-2030: Increasing Adoption of Point-Of-Care (Poc) Testing and the Development of Novel Assays Presents... - August 30th, 2022
- Advancing Precision Oncology, Ochsner Health First to Fully Integrate with Tempus and Epic's Genomics Module - Newswise - August 30th, 2022
- Tiny, Touch-Based Sensor Could Help Patients Stay on Top of Their Medications - SciTechDaily - August 30th, 2022
- Stellar Scholars Join CLAS Faculty - UConn Today - University of Connecticut - August 30th, 2022
- COVID-19 gave new urgency to the science of restoring smell - Science News Magazine - August 30th, 2022
- Dr. Sun lab wins R01 from National Institutes of Health to study liver proteins - Wayne State University - August 22nd, 2022
- Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference - GlobeNewswire - August 22nd, 2022
- New Study Identifies How A Group Of Genes Are Linked To Behavioral Conditions - Forbes - August 22nd, 2022
- New gene variant that protects against coronary heart disease uncovered - EurekAlert - August 22nd, 2022
- How a Japanese Herbal Medicine Protects the Gut Against Inflammatory Bowel Disease - Neuroscience News - August 22nd, 2022
- Insilico Medicine presents on AI for drug discovery at 9th Annual Aging Research and Drug Discovery Conference - EurekAlert - August 22nd, 2022
- Why polio is back on the radar of Canadian health officials - Brighter World - August 22nd, 2022
- Angela DeMichele, MD, MSCE, Assesses the Value of I-SPY2 for Neoadjuvant Treatment of Early Breast Cancer - Cancer Network - August 22nd, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 304753 - Times... - August 22nd, 2022
- Sensor could help patients stay on top of their meds - EurekAlert - August 22nd, 2022
- Trivitron Healthcare launches CoE in metabolomics, genomics, newborn screening and molecular diagnostics - Express Healthcare - August 22nd, 2022
- Research Trends of Moxibustion Therapy for Pain Treatment Over the Pas | JPR - Dove Medical Press - August 22nd, 2022
- Edited Transcript of EXAI.OQ earnings conference call or presentation 18-Aug-22 12:30pm GMT - Yahoo Finance - August 22nd, 2022
- Roche launches COVID-19 test that detects and differentiates the emerging variant of interest BA.2.75 - PR Newswire - August 22nd, 2022
- Will Omicron BA.5 Be the Last of the COVID Variants? - The Epoch Times - August 22nd, 2022
- Many Paths to Failure | Harvard Medical School - Harvard Medical School - August 5th, 2022
- Mitochondrial DNA Mutations Linked to Heart Disease Risk - University of California San Diego - August 5th, 2022
- UC Davis Sets a New Record, Surpasses $1 Billion in Research Funding - University of California, Davis - August 5th, 2022
- A first update on mapping the human genetic architecture of COVID-19 - Nature.com - August 5th, 2022